Downregulation of serum Foxc2 in dilated cardiomyopathy: association with disease severity and cardiac function.

BACKGROUND

Dilated cardiomyopathy (DCM) is one of the most frequent non-ischemic causes of heart failure. Foxc2 has been implicated in cardiovascular disease and angiogenesis, but its role in DCM remains undefined. This study aimed to compare serum Foxc2 levels in DCM and non-DCM patients and to assess its clinical relevance.

METHODS

In this retrospective study, 92 patients (53 DCM, 39 non-DCM) were enrolled. Based on echocardiographic and clinical evaluations, patients were classified into non-DCM group (n = 39) and DCM group (n = 53). Serum Foxc2 concentrations were measured via ELISA, and correlations were analyzed with echocardiographic parameters and biomarkers (BNP, cTnI). ROC analysis assessed Foxc2's diagnostic performance, and Kaplan-Meier analysis evaluated 2-year MACE risk.

RESULTS

Serum Foxc2 levels were significantly lower in the DCM group (35.33 ± 27.99 μg/mL vs. 77.51 ± 28.94 μg/mL), and correlated with cardiac function (positive: LVEF, LVFS; negative: LVEDd, BNP, cTnI). ROC analysis demonstrated high diagnostic accuracy for Foxc2 (AUC 0.862). Patients with Foxc2 levels≥ 33.945 μg/mL showed a reduction in 2-year MACE risk (HR 0.187) compared to those with levels below the threshold.

CONCLUSION

Foxc2 may serve as a promising biomarker for DCM diagnosis and prognosis, supporting for further mechanistic investigations.